Vivos Inc. (RDGL)

Market Cap	56.90M
Revenue (ttm)	28.00K
Net Income (ttm)	-2.91M
Shares Out	453.37M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	56,675
Average Volume	786,216
Open	0.1150
Previous Close	0.1189
Day's Range	0.1150 - 0.1255
52-Week Range	0.0611 - 0.2550
Beta	0.88
RSI	56.68
Earnings Date	Apr 1, 2025

About Vivos

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops an yttrium-90 based precision radionuclide therapy device, RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; IsoPet for the treatment of solid tumors in animals; a universal laboratory cooling device; hydrogel; and other products under the Alpha-Gel, Beta-Gel, Gamma-Gel, and Precisiongel na...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1994
• Employees: 1
• Stock Exchange: OTCMKTS
• Ticker Symbol: RDGL

Financial Performance

In 2024, Vivos's revenue was $27,995, an increase of 43.56% compared to the previous year's $19,500. Losses were -$2.91 million, 0.54% more than in 2023.